According to TipRanks.com, Vendetti is a 3-star analyst with an average return of 1.2% and a 44.4% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Restoration Robotics, and Ellex Medical Lasers.
Currently, the analyst consensus on Sientra is a Strong Buy with an average price target of $13.00, implying a 56.6% upside from current levels. In a report issued on November 5, William Blair also upgraded the stock to Buy.
Based on Sientra’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $37.65 million. In comparison, last year the company had a GAAP net loss of $20.55 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry.